Evaluation of the Efficacy Rate of Rebamipide Combined with Triple Therapy in the Treatment of Senile Peptic Gastric Ulcers
Abstract
Abstract: Objective: To evaluate the efficacy rate of rebamipide combined with triple therapy in the treatment of senile peptic gastric ulcers. Methods: A cohort of 68 elderly patients diagnosed with peptic gastric ulcers was enrolled in this study between January 2022 and December 2024. Using the envelope method for randomization, the patients were divided into two equal groups: a control group administered standard triple therapy and an observation group that received the same triple therapy supplemented with rebamipide. The clinical efficacy, gastric mucosal morphology (mucosal thickness, gland density, active inflammatory cell infiltration, chronic inflammatory cell infiltration), and pepsinogen I/II were compared between the two groups. Results: The total effective rate in the observation group was significantly higher than that in the control group, with a statistically significant difference (p < 0.05). After treatment, the scores of all items in both groups were significantly lower than those before treatment, and the scores in the observation group were significantly lower than those in the control group, with statistically significant differences (p < 0.05). After treatment, the ratios in both groups were significantly higher than those before treatment, and the ratio in the observation group was significantly higher than that in the control group, with statistically significant differences (p < 0.05). Conclusion: Rebamipide combined with triple therapy can significantly improve the treatment efficacy of senile peptic gastric ulcers, effectively improve the histological status of the gastric mucosa, and promote the recovery of gastric mucosal function, with superior efficacy compared to triple therapy alone.
References
Chey W, Howden C, Moss S, et al., 2024, ACG Clinical Guideline: Treatment of Helicobacter Pylori Infection. Am J Gastroenterol, 119(9): 1730–1753.
Zhou H, Jin J, Feng J, et al., 2022, Clinical Value of Triple Therapy Combined with Rebamipide in the Treatment of Elderly Patients with Peptic Gastric Ulcers. Contemporary Medicine, 28(11): 143–144.
Liu Y, 2022, Clinical Study on the Diagnosis and Treatment of 80 Cases of Peptic Gastric Ulcers by Digestive Endoscopy. Contemporary Medicine, 28(4): 99–101.
Lee Y, Dore M, Graham D, et al., 2022, Diagnosis and Treatment of Helicobacter Pylori Infection. Annu Rev Med, 73: 183–195.
Bailey J, 2024, Gastrointestinal Conditions: Peptic Ulcer Disease. FP Essent, 540: 16–23.
Zhu X, 2024, Analysis of the Clinical Effect of Rebamipide Combined with Triple Therapy in the Treatment of Elderly Patients with Peptic Gastric Ulcers. Life Science Instruments, 22(1): 174–176.
Deng S, 2024, Application of Esomeprazole Sodium Combined with Kangfuxin Solution in Patients with Peptic Gastric Ulcers Complicated by Bleeding. Contemporary Medical Journal, 22(18): 44–47.
Shirley M, 2024, Vonoprazan: A Review in Helicobacter Pylori Infection. Erratum in Drugs, 84(5): 621.
Cheng Y, Zhang Q, Zhao B, et al., 2022, Observation of the Effect of Rebamipide in the Treatment of Elderly Patients with Peptic Gastric Ulcers. Journal of Shandong Medical College, 44(5): 355–357.
Hu R, Zhao Y, 2021, Clinical Study on the Treatment of Peptic Gastric Ulcers with Triple Therapy Combined with Rebamipide. Journal of Sichuan Physiological Sciences, 43(11): 1865–1867.
